Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/26406
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | VRANCKX, Pascal | - |
dc.contributor.author | Lewalter, Thorsten | - |
dc.contributor.author | Valgimigli, Marco | - |
dc.contributor.author | Tijssen, Jan G. | - |
dc.contributor.author | Reimitz, Paul-Egbert | - |
dc.contributor.author | Eckardt, Lars | - |
dc.contributor.author | Lanz, Hans-Joachim | - |
dc.contributor.author | Zierhut, Wolfgang | - |
dc.contributor.author | Smolnik, Ruediger | - |
dc.contributor.author | Goette, Andreas | - |
dc.date.accessioned | 2018-07-25T09:21:24Z | - |
dc.date.available | 2018-07-25T09:21:24Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | AMERICAN HEART JOURNAL, 196, p. 105-112 | - |
dc.identifier.issn | 0002-8703 | - |
dc.identifier.uri | http://hdl.handle.net/1942/26406 | - |
dc.description.abstract | Background The optimal antithrombotic treatment after percutaneous coronary intervention (PCI) with stenting in patients with atrial fibrillation (AF) is unknown. In the ENGAGE AF-TIMI 48 trial, edoxaban was noninferior to a vitamin K antagonist (VKA) with respect to the prevention of stroke or systemic embolism and was associated with significantly lower rates of bleeding and cardiovascular death in patients with nonvalvular AF. The effects of edoxaban in combination with singleor dual-antiplatelet therapy in the setting of PCI are unexplored. Design The ENTRUST-AF PCI trial is a multinational, multicenter, randomized, open-label phase 3b trial with blinded end point evaluation involving 1,500 patients on oral anticoagulation for AF. Patients are randomized between 4 hours and 5 days after successful PCI to either an edoxaban-based strategy (experimental arm; 60 mg [or 30 mg according to dose reduction criteria] once daily plus a P2Y12 antagonist [default clopidogrel, 75 mg once daily] for 12 months) or a VKA-based strategy (control arm; VKA plus a P2Y12 antagonist [as above] plus acetylsalicylic acid [100 mg once daily] for 30 days to 12 months). The primary safety end point is the incidence of International Society on Thrombosis and Haemostasis-defined major or clinically relevant nonmajor bleeding. The main efficacy end point is the composite of cardiovascular death, stroke, systemic embolic events, spontaneous myocardial infarction, and definite stent thrombosis. Summary The ENTRUST-AF PCI trial tests the hypothesis that an edoxaban-based antithrombotic strategy reduces the risk of bleeding complications after PCI compared with VKA plus conventional dual-antiplatelet therapy in patients with AF in need of oral anticoagulation. The relative risk of ischemic events between groups will be compared. | - |
dc.description.sponsorship | The ENTRUST-AF PCI study is sponsored by Daiichi Sankyo Europe GmbH. The authors would like to thank the Academic Research Organizations, Atrial Fibrillation NETwork (AFNET e.V.), and ECRI and Shannon Winters, MS, CMPP, for editorial assistance in the preparation of the manuscript. | - |
dc.language.iso | en | - |
dc.rights | © 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | - |
dc.title | Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 112 | - |
dc.identifier.spage | 105 | - |
dc.identifier.volume | 196 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Goette, A (reprint author), St Vincenz Hosp, Cardiol & Intens Care Med, Busdorf 2, D-33098 Paderborn, Nordrhein Westf, Germany. Andreas.Goette@vincenz.de | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.doi | 10.1016/j.ahj.2017.10.009 | - |
dc.identifier.isi | 000424518000013 | - |
item.contributor | VRANCKX, Pascal | - |
item.contributor | Lewalter, Thorsten | - |
item.contributor | Valgimigli, Marco | - |
item.contributor | Tijssen, Jan G. | - |
item.contributor | Reimitz, Paul-Egbert | - |
item.contributor | Eckardt, Lars | - |
item.contributor | Lanz, Hans-Joachim | - |
item.contributor | Zierhut, Wolfgang | - |
item.contributor | Smolnik, Ruediger | - |
item.contributor | Goette, Andreas | - |
item.fullcitation | VRANCKX, Pascal; Lewalter, Thorsten; Valgimigli, Marco; Tijssen, Jan G.; Reimitz, Paul-Egbert; Eckardt, Lars; Lanz, Hans-Joachim; Zierhut, Wolfgang; Smolnik, Ruediger & Goette, Andreas (2018) Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial. In: AMERICAN HEART JOURNAL, 196, p. 105-112. | - |
item.fulltext | With Fulltext | - |
item.accessRights | Open Access | - |
item.validation | ecoom 2019 | - |
crisitem.journal.issn | 0002-8703 | - |
crisitem.journal.eissn | 1097-6744 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S000287031730337X-main.pdf | Published version | 244.81 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
55
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
77
checked on May 26, 2024
Page view(s)
56
checked on Jul 20, 2022
Download(s)
94
checked on Jul 20, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.